Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(2146)
•••
Comment by jdstoxon Feb 27, 2018 12:43pm
220 Views
Post# 27629500

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Hi volume day...

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Hi volume day...Hah, think about that, digitel. Will the Tailwinds portfolio show a higher average when the Bioasis share price goes up?

No, because the Bioasis price is now static in the portfolio. So what does removing it from the portfolio mean? Nothing. It doesn't hurt the portfolio if it goes down further and it shouldn't benefit the portfolio if it goes up because it's not in there, sort of, kind of.

Let's see what he does if this pops. Will he include the pop or not? He shouldn't. And I don't think he'll be able to get it back into the portfolio quickly enough if does pop.

He won't be the only one not able to get in quickly enough if this pops.

In all fairness, you can't get into any stock at yesterday's price if it pops today. Junior stocks are kinda funny that way. Ha ha ha...

Ha!

jdstox

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities